mat

MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2, which is used in cancer research.

MAT2A inhibitor 2 is an inhibitor of methionine adenosyltransferase 2A (MAT2A).

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

MAT2A-IN-10 (Compound 28), an orally active inhibitor of MAT2A, exhibits an IC50 of 26 nM and is utilized in cancer research [1].

MAT2A Allosteric Inhibitor 1, also known as Compound 5, is a selective inhibitor of methionine adenosyltransferase (MAT) demonstrating potent activity with an IC50 value of 6.8 nM [1].

MAT2A Allosteric Inhibitor 2 is a potent, selective inhibitor exhibiting an IC50 of 5 nM and demonstrates nanomolar efficacy (IC50 = 5 μM) in proliferation assays utilizing the MTAP -/- cell line [1].

MAT2A inhibitor 1 is an inhibitor of methionine adenosyltransferase 2A (MATA2) (IC50 < l00 nM).

AGI-25696 is an inhibitor of methionine adenosyltransferase 2A (MATA2). AGI-25696 blocks the growth of MTAP-deleted tumors in vivo and can be used for studies about the treatment of cancer.

PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor with an IC50 of 420 nM and a Kd of 170 nM.

AG-270 is an allosteric and orally active inhibitor of MAT2A.

FIDAS-3, a stilbene derivative and potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A), exhibits anticancer activities by effectively competing with S-adenosylmethionine (SAM) for MAT2A binding.

AGI-24512 is a potent inhibitor of methionine adenylyltransferase 2α (MAT2A) (IC50: 8 nM).AGI-24512 shows antiproliferative activity in MTAP-deficient cancer cells.AGI-24512 inhibits MAT2A, which causes DNA damage in MTAP, and is often used in conjunction with anticancer compounds in cancer research.

Rabies Virus Matrix Protein Fragment (RV-MAT), a polypeptide, selectively binds to the acetylcholine receptor (AChR) on the cell surface [1].

MAT-POS-e194df51-1 is an orally active, non-covalent, non-peptide inhibitor of the SARS-CoV-2 main protease (M^pro) with an IC_50 of 37 nM. It exhibits cytotoxicity, showing EC_50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells [1].

Anti-CD5 Antibody (MAT 304) is an antibody targeting CD5 and can be used for immunology research.

MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.

MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.

MAT2A-IN-19 (Compound I-3) is an inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 32.93 nM.

MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.

MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.

MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.

MAT2A-IN-24 (Compound 9) is an inhibitor of methionine adenosyltransferase 2a (MAT2a), with an IC50 value of 20 nM for MAT2a inhibition and an antiproliferative IC50 value of 10 nM for HAP1MTAP–/– cells. MAT2A-IN-24 is applicable in the research of tumor diseases associated with MTAP deficiency.

MAT2A inhibitor 3 can be used in the cancer research. MAT2A inhibitor 3 is a inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC 50 of <200 nM [1].

MAT2A-IN-4 can be used for the cancer research that is an inhibitor of methionine adenosyltransferase 2A (MAT2A)[1].